Hope Clinical Research

The trials here

What the 17 trials at this site are about, from their registry records.

Conditions

• Migraine4 trials
• Type 2 diabetes4 trials
• Fatty liver disease (MASLD/MASH)3 trials
• Alopecia areata1 trial
• Alzheimer disease1 trial
• Atopic dermatitis (eczema)1 trial
• Colorectal cancer1 trial
• High blood pressure1 trial
• Liver cirrhosis1 trial
• Long COVID and ME/CFS1 trial
• Type 1 diabetes1 trial

Phase

• Phase 27 trials
• Phase 35 trials
• Phase 2/32 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed6 trials
• Recruiting6 trials
• Active, not recruiting4 trials
• Terminated1 trial

Lead sponsor

• Pfizer4 trials
• Biomea Fusion Inc.3 trials
• Boehringer Ingelheim3 trials
• AIM ImmunoTech Inc.1 trial
• Annovis Bio Inc.1 trial
• and 5 more

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

  NCT07729462· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

  NCT07609914· Phase 4· Pfizer· Source

• Recruiting

  Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

  NCT07502508· Phase 2· Biomea Fusion Inc.· Source

  Contact: Biomea Fusion Inc.

• Active, not recruiting

  Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

  NCT07502495· Phase 2· Biomea Fusion Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Annovis Bio Inc.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Guardant Health, Inc.· Source

• Active, not recruiting

  Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  NCT03898479· Phase 2/3· Sun Pharmaceutical Industries, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)2 recruiting
• Migraine2 recruiting
• Type 2 diabetes2 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

  NCT06848075· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

  NCT05592418· Phase 2· AIM ImmunoTech Inc.· Source

• Completed

  Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

  NCT05731544· Phase 1/2· Biomea Fusion Inc.· Source

• Completed

  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

  NCT05469464· Phase 2· UNION therapeutics· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source